Gate2Brain is a Norwegian biotechnology company founded in 2018 that develops technology to enhance drug delivery across the blood-brain barrier for treating neurological diseases. The company's proprietary platform uses engineered peptides and delivery systems to transport therapeutic molecules into the brain, addressing one of the major challenges in neuropharmacology. Their technology has potential applications in treating conditions like Alzheimer's disease, Parkinson's disease, and brain tumors. Gate2Brain collaborates with pharmaceutical companies to improve the efficacy of existing drugs and enable new therapeutic approaches for neurological disorders.
Gate2Brain has received investment from 1 venture capital firm.
Norwegian biotech company developing blood-brain barrier technology to improve drug delivery for treating neurological diseases.
Gate2Brain has received investment from Asabys Partners. These venture capital firms and investors provide both capital and strategic support.
Gate2Brain has raised $5M in total funding, with their most recent round being a Seed. The company operates in the Biotech sector.
Gate2Brain was founded in 2018 and is headquartered in Bergen, Norway.
Gate2Brain operates in the Biotech sector. Norwegian biotech company developing blood-brain barrier technology to improve drug delivery for treating neurological diseases.
